|
1
|
Holohan C, Van Schaeybroeck S, Longley DB
and Johnston PG: Cancer drug resistance: An evolving paradigm. Nat
Rev Cancer. 13:714–726. 2013.PubMed/NCBI View Article : Google Scholar
|
|
2
|
Vasan N, Baselga J and Hyman DM: A view on
drug resistance in cancer. Nature. 575:299–309. 2019.PubMed/NCBI View Article : Google Scholar
|
|
3
|
Zhu H, Luo H, Zhang W, Shen Z, Hu X and
Zhu X: Molecular mechanisms of cisplatin resistance in cervical
cancer. Drug Des Devel Ther. 10:1885–1895. 2016.PubMed/NCBI View Article : Google Scholar
|
|
4
|
Nikolaou M, Pavlopoulou A, Georgakilas AG
and Kyrodimos E: The challenge of drug resistance in cancer
treatment: A current overview. Clin Exp Metastasis. 35:309–318.
2018.PubMed/NCBI View Article : Google Scholar
|
|
5
|
Panda M and Biswal BK: Cell signaling and
cancer: A mechanistic insight into drug resistance. Mol Biol Rep.
46:5645–5659. 2019.PubMed/NCBI View Article : Google Scholar
|
|
6
|
Salgia R and Kulkarni P: The
genetic/non-genetic duality of drug ‘resistance’ in cancer. Trends
Cancer. 4:110–118. 2018.PubMed/NCBI View Article : Google Scholar
|
|
7
|
Kartal-Yandim M, Adan-Gokbulut A and Baran
Y: Molecular mechanisms of drug resistance and its reversal in
cancer. Crit Rev Biotechnol. 36:716–726. 2016.PubMed/NCBI View Article : Google Scholar
|
|
8
|
Chatterjee N and Bivona TG: Polytherapy
and Targeted Cancer Drug Resistance. Trends Cancer. 5:170–182.
2019.PubMed/NCBI View Article : Google Scholar
|
|
9
|
Hirose M, Hosoi E, Hamano S and Jalili A:
Multidrug resistance in hematological malignancy. J Med Invest.
50:126–135. 2003.PubMed/NCBI
|
|
10
|
Hackl H, Astanina K and Wieser R:
Molecular and genetic alterations associated with therapy
resistance and relapse of acute myeloid leukemia. J Hematol Oncol.
10(51)2017.PubMed/NCBI View Article : Google Scholar
|
|
11
|
Waghray D and Zhang Q: Inhibit or evade
multidrug resistance P-glycoprotein in cancer treatment. J Med
Chem. 61:5108–5121. 2018.PubMed/NCBI View Article : Google Scholar
|
|
12
|
Ferlay J, Soerjomataram I, Dikshit R, Eser
S, Mathers C, Rebelo M, Parkin DM, Forman D and Bray F: Cancer
incidence and mortality worldwide: Sources, methods and major
patterns in GLOBOCAN 2012. Int J Cancer. 136:E359–E386.
2015.PubMed/NCBI View Article : Google Scholar
|
|
13
|
Wu C: Systemic therapy for colon cancer.
Surg Oncol Clin N Am. 27:235–242. 2018.PubMed/NCBI View Article : Google Scholar
|
|
14
|
Hu T, Li Z, Gao CY and Cho CH: Mechanisms
of drug resistance in colon cancer and its therapeutic strategies.
World J Gastroenterol. 22:6876–6889. 2016.PubMed/NCBI View Article : Google Scholar
|
|
15
|
Han B, Feng D, Yu X, Zhang Y, Liu Y and
Zhou L: Identification and interaction analysis of molecular
markers in colorectal cancer by integrated bioinformatics analysis.
Med Sci Monit. 24:6059–6069. 2018.PubMed/NCBI View Article : Google Scholar
|
|
16
|
Irham LM, Wong HS, Chou WH, Adikusuma W,
Mugiyanto E, Huang WC and Chang WC: Integration of genetic variants
and gene network for drug repurposing in colorectal cancer.
Pharmacol Res. 161(105203)2020.PubMed/NCBI View Article : Google Scholar
|
|
17
|
Zhang X, Zhang H, Shen B and Sun XF: Novel
MicroRNA biomarkers for colorectal cancer early diagnosis and
5-fluorouracil chemotherapy resistance but not prognosis: A atudy
from databases to AI-assisted verifications. Cancers (Basel).
12(E341)2020.PubMed/NCBI View Article : Google Scholar
|
|
18
|
Edge SB, Byrd DR, Compton CC, Fritz AG,
Greene FL and Trotti A (eds): AJCC Cancer Staging Manual. 7th
edition. Springer, New York, NY, 2010.
|
|
19
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) method. Methods. 25:402–408.
2001.PubMed/NCBI View Article : Google Scholar
|
|
20
|
Li Q, Lai Z, Yan Z, Peng J, Jin Y, Wei L
and Lin J: Hedyotis diffusa Willd inhibits proliferation and
induces apoptosis of 5 FU resistant colorectal cancer cells by
regulating the PI3K/AKT signaling pathway. Mol Med Rep. 17:358–365.
2018.PubMed/NCBI View Article : Google Scholar
|
|
21
|
Li Q, Wei L, Lin S, Chen Y, Lin J and Peng
J: Synergistic effect of kaempferol and 5 fluorouracil on the
growth of colorectal cancer cells by regulating the PI3K/Akt
signaling pathway. Mol Med Rep. 20:728–734. 2019.PubMed/NCBI View Article : Google Scholar
|
|
22
|
Fallah J and Rini BI: HIF Inhibitors:
Status of current clinical Development. Curr Oncol Rep.
21(6)2019.PubMed/NCBI View Article : Google Scholar
|
|
23
|
Feng X, Liu H, Zhang Z, Gu Y, Qiu H and He
Z: Annexin A2 contributes to cisplatin resistance by activation of
JNK-p53 pathway in non-small cell lung cancer cells. J Exp Clin
Cancer Res. 36(123)2017.PubMed/NCBI View Article : Google Scholar
|
|
24
|
Zhao F and Lam EW: Role of the forkhead
transcription factor FOXO-FOXM1 axis in cancer and drug resistance.
Front Med. 6:376–380. 2012.PubMed/NCBI View Article : Google Scholar
|
|
25
|
Lai M, Liu G, Li R, Bai H, Zhao J, Xiao P
and Mei J: Hsa_circ_0079662 induces the resistance mechanism of the
chemotherapy drug oxaliplatin through the TNF-α pathway in human
colon cancer. J Cell Mol Med. 24:5021–5027. 2020.PubMed/NCBI View Article : Google Scholar
|
|
26
|
Kozovska Z, Gabrisova V and Kucerova L:
Colon cancer: cancer stem cells markers, drug resistance and
treatment. Biomed Pharmacother. 68:911–916. 2014.PubMed/NCBI View Article : Google Scholar
|
|
27
|
Yuan Z, Shi X, Qiu Y, Jia T, Yuan X, Zou
Y, Liu C, Yu H, Yuan Y, He X, et al: Reversal of P-gp-mediated
multidrug resistance in colon cancer by cinobufagin. Oncol Rep.
37:1815–1825. 2017.PubMed/NCBI View Article : Google Scholar
|
|
28
|
Hu T, To KK, Wang L, Zhang L, Lu L, Shen
J, Chan RL, Li M, Yeung JH and Cho CH: Reversal of P-glycoprotein
(P-gp) mediated multidrug resistance in colon cancer cells by
cryptotanshinone and dihydrotanshinone of Salvia
miltiorrhiza. Phytomedicine. 21:1264–1272. 2014.PubMed/NCBI View Article : Google Scholar
|
|
29
|
Abu-Sanad A, Wang Y, Hasheminasab F,
Panasci J, Noë A, Rosca L, Davidson D, Amrein L, Sharif-Askari B,
Aloyz R, et al: Simultaneous inhibition of ATR and PARP sensitizes
colon cancer cell lines to irinotecan. Front Pharmacol.
6(147)2015.PubMed/NCBI View Article : Google Scholar
|
|
30
|
Zhou Y, Wan G, Spizzo R, Ivan C, Mathur R,
Hu X, Ye X, Lu J, Fan F, Xia L, et al: miR-203 induces oxaliplatin
resistance in colorectal cancer cells by negatively regulating ATM
kinase. Mol Oncol. 8:83–92. 2014.PubMed/NCBI View Article : Google Scholar
|
|
31
|
Alimperti S and Andreadis ST: CDH2 and
CDH11 act as regulators of stem cell fate decisions. Stem Cell Res
(Amst). 14:270–282. 2015.PubMed/NCBI View Article : Google Scholar
|
|
32
|
Loh CY, Chai JY, Tang TF, Wong WF, Sethi
G, Shanmugam MK, Chong PP and Looi CY: The E-cadherin and
N-cadherin switch in epithelial-to-mesenchymal transition:
Signaling, therapeutic implications, and challenges. Cells.
8(E1118)2019.PubMed/NCBI View Article : Google Scholar
|
|
33
|
Serova M, Astorgues-Xerri L, Bieche I,
Albert S, Vidaud M, Benhadji KA, Emami S, Vidaud D, Hammel P,
Theou-Anton N, et al: Epithelial-to-mesenchymal transition and
oncogenic Ras expression in resistance to the protein kinase Cbeta
inhibitor enzastaurin in colon cancer cells. Mol Cancer Ther.
9:1308–1317. 2010.PubMed/NCBI View Article : Google Scholar
|
|
34
|
Tomida C, Yamagishi N, Nagano H, Uchida T,
Ohno A, Hirasaka K, Nikawa T and Teshima-Kondo S: VEGF
pathway-targeting drugs induce evasive adaptation by activation of
neuropilin-1/cMet in colon cancer cells. Int J Oncol. 52:1350–1362.
2018.PubMed/NCBI View Article : Google Scholar
|
|
35
|
Zhang Y and Chua S Jr: Leptin function and
regulation. Compr Physiol. 8:351–369. 2017.PubMed/NCBI View Article : Google Scholar
|
|
36
|
Lipsey CC, Harbuzariu A, Robey RW, Huff
LM, Gottesman MM and Gonzalez-Perez RR: Leptin signaling affects
survival and chemoresistance of estrogen receptor negative breast
cancer. Int J Mol Sci. 21(E3794)2020.PubMed/NCBI View Article : Google Scholar
|
|
37
|
Lao G, Ren M, Wang X, Zhang J, Huang Y,
Liu D, Luo H, Yang C and Yan L: Human tissue inhibitor of
metalloproteinases-1 improved wound healing in diabetes through its
anti-apoptotic effect. Exp Dermatol. 28:528–535. 2019.PubMed/NCBI View Article : Google Scholar
|
|
38
|
Lee JH, Choi JW and Kim YS: Serum TIMP-1
predicts survival outcomes of invasive breast carcinoma patients: A
meta-analysis. Arch Med Res. 42:463–468. 2011.PubMed/NCBI View Article : Google Scholar
|
|
39
|
Tan Y, Li X, Tian Z, Chen S, Zou J, Lian
G, Chen S, Huang K and Chen Y: TIMP1 down-regulation enhances
gemcitabine sensitivity and reverses chemoresistance in pancreatic
cancer. Biochem Pharmacol. 189(114085)2021.PubMed/NCBI View Article : Google Scholar
|
|
40
|
Liu C, Feng X, Wang B, Wang X, Wang C, Yu
M, Cao G and Wang H: Bone marrow mesenchymal stem cells promote
head and neck cancer progression through Periostin-mediated
phosphoinositide 3-kinase/Akt/mammalian target of rapamycin. Cancer
Sci. 109:688–698. 2018.PubMed/NCBI View Article : Google Scholar
|
|
41
|
Xiao ZM, Wang XY and Wang AM: Periostin
induces chemoresistance in colon cancer cells through activation of
the PI3K/Akt/survivin pathway. Biotechnol Appl Biochem. 62:401–406.
2015.PubMed/NCBI View Article : Google Scholar
|
|
42
|
Ratajczak-Wielgomas K, Kmiecik A,
Grzegrzołka J, Piotrowska A, Gomulkiewicz A, Partynska A, Pawelczyk
K, Nowinska K, Podhorska-Okolow M and Dziegiel P: Prognostic
significance of stromal periostin expression in non-small cell lung
cancer. Int J Mol Sci. 21(E7025)2020.PubMed/NCBI View Article : Google Scholar
|
|
43
|
Park SY, Piao Y, Jeong KJ, Dong J and de
Groot JF: Periostin (POSTN) regulates tumor resistance to
antiangiogenic therapy in glioma models. Mol Cancer Ther.
15:2187–2197. 2016.PubMed/NCBI View Article : Google Scholar
|
